10-Q: AccuStem Sciences Reports Q1 2025 Results, Focuses on Commercialization of Genomic Tests

AccuStem Sciences reports a net loss for Q1 2025 while advancing the commercialization of its MSC lung test and StemPrintER breast cancer test.

Summary

• AccuStem Sciences, an early-stage life sciences company, released its financial results for the first quarter of 2025.
• The company is focused on developing and commercializing novel genomic tests for cancer management, particularly for breast and lung cancer.
• AccuStem reported a net loss of $440,408 for the three months ended March 31, 2025, compared to a net loss of $526,602 for the same period in 2024.
• As of March 31, 2025, the company had an accumulated deficit of $8,467,455.
• The company's lead product candidates are the microRNA Signature Classifier (MSC) test for lung nodules and StemPrintER for early-stage breast cancer.
• AccuStem plans to launch the MSC test for clinical use in early 2026 and is working on transferring the test to a commercial laboratory and obtaining CLIA certification.
• The company anticipates needing additional funds to support its operations and is actively pursuing equity financing.
• Research and development expenses increased to $28,346 for the three months ended March 31, 2025, compared to $23,197 for the three months ended March 31, 2024.
• General and administrative expenses decreased to $412,062 for the three months ended March 31, 2025, compared to $503,405 for the three months ended March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress in commercializing its products and has reduced its net loss compared to the previous year, it faces significant financial challenges, including a low cash balance, an accumulated deficit, and a material weakness in internal controls. The need for additional financing and the uncertainties surrounding product development and commercialization contribute to a cautious sentiment.

Positives

• The net loss decreased from $526,602 in Q1 2024 to $440,408 in Q1 2025.
• General and administrative expenses decreased from $503,405 to $412,062.
• The company is making progress in commercializing its MSC lung test, with plans to launch in early 2026.
• AccuStem has partnered with EmeritusDx for laboratory processing of the MSC test.
• The company is actively pursuing additional equity financing.

Negatives

• The company reported a net loss of $440,408 for Q1 2025.
• AccuStem has an accumulated deficit of $8,467,455 as of March 31, 2025.
• The company's cash balance of $36,381 is considered inadequate for current planned operations.
• There is a material weakness in internal controls over financial reporting due to a lack of accounting resources.

Risks

• The company's ability to fund its operations depends on securing additional financing.
• There is no assurance that additional financing will be available on favorable terms or at all.
• Failure to obtain additional financing could force the company to delay, reduce, or eliminate research and development programs.
• The company has a material weakness in internal controls over financial reporting.
• The company has not generated revenue to date and has incurred significant operating losses since inception.
• The company's potential products are at various phases of development and may not be successfully commercialized.
• The company's cash balance is inadequate for current planned operations and will be sufficient to fund operations and capital expenditure requirements until June 2025.

Future Outlook

AccuStem plans to launch its MSC test for clinical use in early 2026 and is working on transferring the test to a commercial laboratory and obtaining CLIA certification. The company also plans to launch StemPrintER in the US and expand to other markets. AccuStem expects to incur net losses for the foreseeable future and will need additional funds to support its operations.

Management Comments

• Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these condensed consolidated financial statements, and will require significant additional cash resources to continue its planned research and development activities.
• Management intends to remediate this item in the following manner: i. Recruit appropriately skilled accounting resources (the Remediation Plan).

Industry Context

AccuStem Sciences operates in the competitive field of cancer diagnostics, focusing on genomic tests for personalized medicine. The company's focus on lung and breast cancer aligns with the significant global burden of these diseases and the growing demand for more accurate and personalized diagnostic tools. The development and commercialization of MSC and StemPrintER are aimed at addressing unmet clinical needs in the management of lung nodules and early-stage breast cancer, respectively.

Comparison to Industry Standards

• AccuStem's StemPrintER test is similar to Exact Science's Oncotype DX Breast Recurrence Score and Myriad Genetics' Prolaris test, which also provide prognostic information for breast cancer patients.
• These tests help guide treatment decisions by assessing the risk of recurrence.
• The MSC lung test is similar to Veracyte's Percepta Nasal Swab test, which is designed to improve the accuracy of lung cancer diagnosis in patients with lung nodules.
• These tests aim to reduce the number of unnecessary invasive procedures and improve patient outcomes.
• Compared to larger diagnostic companies like Roche and Qiagen, AccuStem is a smaller, early-stage company focused on developing and commercializing novel genomic tests.
• AccuStem's success will depend on its ability to secure funding, validate its tests in clinical studies, and obtain regulatory approvals and reimbursement.

Related Party Transactions

• The Company and Tiziana share directors, officers and significant shareholders.
• The Company has also been formed due to an acquisition of a subsidiary company from Tiziana.
• As of March 31, 2025, Tiziana owns approximately 10.91 % of the Company.
• Effective with the demerger agreement, the Company entered into a shared services agreement, where the Company outsources certain limited management and administrative services.
• In January 2022, the Company and Gabriele Cerrone, who is the Chairman of the Board of Directors and the largest shareholder, entered into an agreement in which he will provide consulting services to the Company for a monthly fee of $ 5,500 .

Stakeholder Impact

• Shareholders face potential dilution from future equity financings.
• Employees may be affected by potential delays or reductions in research and development programs if the company fails to secure additional funding.
• Customers (patients and healthcare providers) may benefit from the commercialization of new diagnostic tests for cancer management.
• Suppliers and creditors may be impacted by the company's financial challenges and its ability to meet its obligations.

Next Steps

• Transfer MSC from the laboratory in which it was developed to a commercial laboratory in the US.
• Obtain U.S. Clinical Laboratory Improvement Amendments of 1988 (CLIA) certification.
• Launch StemPrintER in the US and then expand to other markets.
• Validate and commercialize StemPrint in a variety of different tumor types.

Key Dates

Keywords

AccuStem Sciences, genomic tests, MSC lung test, StemPrintER, cancer diagnostics, financial results, Q1 2025, commercialization, equity financing, CLIA certification